Novartis shares drop after del-desiran misses trial endpoint
Novartis stock fell 10.1% to $138.51 after del-desiran missed the primary endpoint in a myotonic-dystrophy trial, Reuters reported. The move erased about CHF24 billion in market value.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.